---
title: "Oxymorphone - Complete Profile"
substance: "Oxymorphone"
chemical_name: "4,5ﾎｱ-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one"
category: "Depressant"
legal_status: "Schedule II (US), Schedule I (UK)"
description: "The most potent prescription opioid - Opana's extreme euphoria and injection epidemic made it both coveted street drug and pharmaceutical nightmare"
permalink: "/dyos-domain/substances/oxymorphone/"
---

<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> 竊・<a href="/dyos-domain/depressants/">Depressants</a> 竊・<span>Oxymorphone</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>汳 Oxymorphone</h1>
        <h2 class="chemical-name">4,5ﾎｱ-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Oxymorphone" 
                data-category="Depressants" 
                data-chemical="4,5ﾎｱ-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Opana</span> 窶｢ <span>Opana ER</span> 窶｢ <span>Numorphan</span> 窶｢ <span>Oxymorphone HCl</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Pink Pills</span> 窶｢ <span>Pink Lady</span> 窶｢ <span>O-Bomb</span> 窶｢ <span>Stop Signs</span> 窶｢ <span>Blues</span>
            </div>
            <div class="name-category">
              <h4>Injection Culture</h4>
              <span>Pandas</span> 窶｢ <span>Biscuits</span> 窶｢ <span>Peaches</span> 窶｢ <span>Pink Death</span> 窶｢ <span>Hospital Heroin</span>
            </div>
            <div class="name-category">
              <h4>Chemical</h4>
              <span>Oxymorphone Hydrochloride</span> 窶｢ <span>14-Hydroxydihydromorphinone</span> 窶｢ <span>6-Deoxymorphine</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category medical-opioid">Medical Opioid</span>
          <span class="legal-status schedule-2">Schedule II</span>
          <span class="duration short">3-6 hours (IR) / 12 hours (ER)</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="{{ '/assets/substances/oxymorphone.jpg' | url }}" alt="Opana tablets, injectable vials, and extended-release formulations showing the most potent prescription opioid preparations" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>洫ｬ C竄≫ｇH竄≫ｉNO竄・/p>
            <p>MW: 301.34 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>沐 Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pharmaceutical Forms</h4>
          <ul>
            <li><strong>Immediate-release tablets:</strong> Pink round tablets (5mg, 10mg) with "E" imprints</li>
            <li><strong>Extended-release tablets:</strong> Yellow/orange Opana ER (5-40mg) tamper-resistant</li>
            <li><strong>Injectable solutions:</strong> Clear, colorless liquid in vials (1mg/mL, 1.5mg/mL)</li>
            <li><strong>Suppositories:</strong> 5mg rectal suppositories for medical use</li>
            <li><strong>Original Opana tablets:</strong> Easily crushable pink tablets (discontinued 2012)</li>
            <li><strong>Generic formulations:</strong> Various manufacturers with different appearances</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Diverted Medical Forms</h4>
          <ul>
            <li><strong>Pink Opana tablets:</strong> Original IR formulation, highly sought for injection</li>
            <li><strong>Opana ER tablets:</strong> Yellow extended-release, tamper-resistant but still abused</li>
            <li><strong>Injectable oxymorphone:</strong> Hospital vials for IV/IM administration</li>
            <li><strong>Crushed tablet powder:</strong> IR tablets ground for snorting or injection</li>
            <li><strong>Generic oxymorphone:</strong> Various imprints and colors from different manufacturers</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>笞・・Injection Epidemic & Contamination</h4>
          <p><strong>HIV/Hepatitis outbreaks:</strong> Indiana 2015 outbreak traced to Opana injection sharing</p>
          <p><strong>Injection preparation:</strong> Tablets not designed for IV use cause vein damage</p>
          <p><strong>Counterfeit tablets:</strong> Street "oxymorphone" may contain fentanyl</p>
          <p><strong>Cross-contamination:</strong> Shared injection equipment spreads blood-borne diseases</p>
          <p><strong>Adulterant toxicity:</strong> Tablet fillers cause serious injection complications</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>汳 Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">1-2.5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">2.5-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">5-15mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">15-30mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">30mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosing (Hospital/Prescription)</h4>
        <ul>
          <li><strong>Severe pain (IV):</strong> 0.5-1.5mg every 4-6 hours PRN</li>
          <li><strong>Severe pain (oral):</strong> 5-10mg every 4-6 hours PRN</li>
          <li><strong>Extended-release:</strong> 5-40mg every 12 hours</li>
          <li><strong>Opioid conversion:</strong> ~3x more potent than oxycodone</li>
          <li><strong>Cancer pain:</strong> Doses titrated to effect (can be very high)</li>
        </ul>
        
        <h4>笞・・EXTREME POTENCY WARNINGS</h4>
        <ul>
          <li><strong>3x oxycodone potency:</strong> 10mg oxymorphone 竕・30mg oxycodone</li>
          <li><strong>6-10x morphine potency:</strong> Extremely small therapeutic doses</li>
          <li><strong>Injection multiplication:</strong> IV/IM dramatically increases potency and overdose risk</li>
          <li><strong>Opioid-naive danger:</strong> 5-10mg oral can cause respiratory depression</li>
          <li><strong>Tolerance variability:</strong> Rapid tolerance development with dose escalation</li>
        </ul>
        
        <h4>泅ｨ Injection Epidemic Context</h4>
        <ul>
          <li><strong>Indiana HIV outbreak:</strong> 200+ cases from shared Opana injection (2015)</li>
          <li><strong>Rural injection epidemic:</strong> Appalachian communities devastated by Opana injection</li>
          <li><strong>Vein collapse:</strong> Tablet fillers cause severe venous damage</li>
          <li><strong>Blood-borne disease:</strong> Hepatitis C, HIV transmission through shared needles</li>
          <li><strong>Emergency room surge:</strong> Injection complications overwhelm rural hospitals</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>MEDICAL SUPERVISION REQUIRED:</strong> Oxymorphone's extreme potency makes it extremely dangerous without medical supervision and appropriate tolerance.</p>
    </div>

    <div class="profile-section effects">
      <h3>笨ｨ Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Intravenous)</h4>
        <div class="timeline-item">
          <span class="time">T+0:01-0:03</span>
          <span class="effect">Onset - immediate intense euphoria rush</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:05-0:30</span>
          <span class="effect">Peak - maximum analgesia and euphoric effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-6:00</span>
          <span class="effect">Duration - sustained but shorter than oral</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00+</span>
          <span class="effect">Comedown - rapid offset, intense craving</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category therapeutic">
          <h4>笨・Medical Effects</h4>
          <ul>
            <li>Extremely powerful analgesia</li>
            <li>Rapid onset of pain relief</li>
            <li>Effective for severe, breakthrough pain</li>
            <li>Anxiety and distress reduction</li>
            <li>Sedation and tranquility</li>
            <li>Cough suppression</li>
          </ul>
        </div>
        
        <div class="effect-category recreational">
          <h4>沁ｯ Sought Effects (Abuse)</h4>
          <ul>
            <li>Intense, immediate euphoria (IV)</li>
            <li>Profound sense of wellbeing</li>
            <li>Complete emotional numbing</li>
            <li>Escape from psychological pain</li>
            <li>Warm, embracing sensation</li>
            <li>Dissociation from problems</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>笶・Adverse Effects</h4>
          <ul>
            <li>Severe respiratory depression</li>
            <li>Extreme constipation</li>
            <li>Nausea and vomiting</li>
            <li>Profound drowsiness</li>
            <li>Cognitive impairment</li>
            <li>Rapid physical dependence</li>
            <li>Injection site damage</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>洫 Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Oxymorphone is a potent semi-synthetic ﾎｼ-opioid receptor agonist with exceptional binding affinity and intrinsic activity. Structurally related to morphine but with a 14-hydroxyl group that dramatically increases potency and euphoric potential. It demonstrates superior CNS penetration compared to morphine and produces more intense euphoria per unit of analgesia, contributing to its high abuse potential. The drug activates ﾎｼ-opioid receptors throughout pain pathways and reward circuits with remarkable efficiency.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>ﾎｼ-opioid receptor (MOR)</strong></span>
            <span class="affinity">Very high affinity (Ki: ~0.5 nM)</span>
            <span class="function">Primary analgesia, intense euphoria, respiratory depression</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>ﾎｴ-opioid receptor (DOR)</strong></span>
            <span class="affinity">Moderate affinity (~20 nM)</span>
            <span class="function">Additional analgesia, mood effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>ﾎｺ-opioid receptor (KOR)</strong></span>
            <span class="affinity">Low affinity (~100 nM)</span>
            <span class="function">Minimal contribution to effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptor</strong></span>
            <span class="affinity">Weak antagonist activity</span>
            <span class="function">May contribute to analgesic synergy</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A receptor</strong></span>
            <span class="affinity">Indirect modulation</span>
            <span class="function">Enhanced sedation through opioid pathways</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Glucuronidation by UGT2B7 竊・oxymorphone-3-glucuronide (inactive)</p>
          <p><strong>Minor Pathway:</strong> 6-OH reduction 竊・oxycodol (less active)</p>
          <p><strong>Half-life:</strong> 7-9 hours (oral), 1-3 hours (IV)</p>
          <p><strong>Bioavailability:</strong> 100% (IV), 10% (oral - extensive first-pass metabolism)</p>
          <p><strong>Peak plasma:</strong> 2-5 minutes (IV), 1-2 hours (oral)</p>
          <p><strong>Protein binding:</strong> 10-12% (low binding)</p>
          <p><strong>Route-dependent potency:</strong> IV/IM much more potent than oral</p>
        </div>

        <h4>Superior Euphoric Profile</h4>
        <div class="euphoria-profile-info">
          <p><strong>High euphoria-to-analgesia ratio:</strong> More rewarding per unit of pain relief than morphine</p>
          <p><strong>Rapid CNS penetration:</strong> Crosses blood-brain barrier more efficiently</p>
          <p><strong>Intense ﾎｼ-opioid activation:</strong> Produces profound reward pathway stimulation</p>
          <p><strong>Short onset time:</strong> IV effects within seconds, creating intense "rush"</p>
          <p><strong>High abuse liability:</strong> Considered among most rewarding prescription opioids</p>
        </div>

        <h4>Tolerance and Dependence</h4>
        <div class="dependence-info">
          <p><strong>Rapid tolerance:</strong> Develops within days of regular use</p>
          <p><strong>Cross-tolerance:</strong> Complete with all ﾎｼ-opioid agonists</p>
          <p><strong>Physical dependence:</strong> Can develop after single medical exposure</p>
          <p><strong>Withdrawal syndrome:</strong> Onset 4-8 hours, peak 48-72 hours, duration 7-14 days</p>
          <p><strong>Psychological dependence:</strong> Intense craving due to superior euphoric profile</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Extreme potency:</strong> 3x more potent than oxycodone, 6-10x more than morphine</li>
          <li><strong>Route-dependent effects:</strong> Dramatic potency increase with injection</li>
          <li><strong>Superior reward profile:</strong> Higher euphoria-to-analgesia ratio</li>
          <li><strong>14-hydroxyl group:</strong> Key structural feature enhancing potency and CNS effects</li>
          <li><strong>Low oral bioavailability:</strong> Extensive first-pass metabolism limits oral abuse potential</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>笞・・Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>泅ｨ EXTREME DANGER</h4>
          <ul>
            <li><strong>Extreme potency:</strong> 3x oxycodone, 6-10x morphine - tiny amounts can be fatal</li>
            <li><strong>Injection epidemic:</strong> Caused major HIV/Hepatitis outbreaks in rural communities</li>
            <li><strong>Rapid respiratory depression:</strong> Can stop breathing within minutes (IV)</li>
            <li><strong>Vein damage:</strong> Tablet fillers cause severe venous damage and collapse</li>
            <li><strong>Blood-borne disease:</strong> Extremely high transmission risk through shared needles</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>泝｡・・Critical Harm Reduction</h4>
          <ul>
            <li>NEVER use alone - have someone present who can call 911</li>
            <li>Carry multiple naloxone doses - may need 4-6 doses for oxymorphone</li>
            <li>Start with microscopic test doses - extreme potency variability</li>
            <li>Avoid injection completely - designed for oral use only</li>
            <li>Use sterile equipment if injecting despite warnings</li>
            <li>Know signs of overdose and respiratory depression</li>
            <li>Seek medical detox for withdrawal - extremely severe</li>
          </ul>
        </div>
      </div>

      <div class="injection-epidemic">
        <h4>汳 Injection Epidemic Crisis</h4>
        <p><strong>Indiana HIV outbreak:</strong> 200+ cases traced to shared Opana injection in rural community. <strong>Vein damage:</strong> Tablet fillers cause "concrete veins" and permanent damage. <strong>Disease transmission:</strong> Hepatitis C rates 15x national average in affected areas. <strong>Medical emergency:</strong> Rural hospitals overwhelmed with injection complications. <strong>Public health crisis:</strong> Destroyed entire communities through blood-borne disease spread.</p>
      </div>

      <div name="naloxone-response">
        <h4>泅 Overdose Response</h4>
        <p><strong>Call 911 first.</strong> Administer naloxone immediately - intranasal or auto-injector. <strong>Multiple doses essential:</strong> Oxymorphone may require 4-6 naloxone doses. <strong>Rescue breathing:</strong> Provide mouth-to-mouth if trained. <strong>Recovery position:</strong> Turn on side to prevent choking. <strong>Extended monitoring:</strong> Naloxone duration much shorter than oxymorphone - overdose can return.</p>
      </div>

      <div class="contraindications">
        <h4>泅ｫ Absolute Contraindications</h4>
        <p><strong>DO NOT USE:</strong> If opioid-naive without medical supervision, with any alcohol/depressants, alone, without naloxone, if pregnant, with respiratory conditions. <strong>NEVER INJECT</strong> tablets not designed for injection. <strong>Medical supervision only</strong> for legitimate severe pain in appropriate settings.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>笞暦ｸ・Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>沐ｴ FATAL COMBINATIONS</h4>
          <ul>
            <li><strong>Alcohol:</strong> Synergistic respiratory depression - extremely high death rate</li>
            <li><strong>Benzodiazepines:</strong> Multiplicative CNS depression effects</li>
            <li><strong>Barbiturates:</strong> Additive respiratory depression</li>
            <li><strong>Other opioids:</strong> Unpredictable potentiation effects</li>
            <li><strong>Sleep medications:</strong> Z-drugs, sedative-hypnotics compound effects</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>沺｡ High Risk</h4>
          <ul>
            <li><strong>Gabapentinoids:</strong> Pregabalin, gabapentin increase respiratory depression</li>
            <li><strong>Muscle relaxants:</strong> Enhanced sedation and respiratory depression</li>
            <li><strong>Antihistamines:</strong> Increased sedation and confusion</li>
            <li><strong>Antipsychotics:</strong> Enhanced sedation, orthostatic hypotension</li>
          </ul>
        </div>
        
        <div class="interaction moderate">
          <h4>沺 Moderate Risk</h4>
          <ul>
            <li><strong>MAOIs:</strong> Risk of serotonin syndrome and respiratory depression</li>
            <li><strong>Tricyclic antidepressants:</strong> Enhanced sedation, anticholinergic effects</li>
            <li><strong>Beta-blockers:</strong> May mask overdose warning signs</li>
            <li><strong>Diuretics:</strong> Risk of dehydration and electrolyte imbalance</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>笞厄ｸ・Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>氈E氈E United States</h4>
            <p><strong>Schedule II</strong> - Legal by prescription only for severe pain. High potential for abuse with severe psychological and physical dependence. Strict DEA oversight and tracking.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E United Kingdom</h4>
            <p><strong>Schedule I (Class A)</strong> - Controlled drug, prescription only. Illegal possession without prescription carries up to 7 years imprisonment. Supply: life imprisonment.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E Canada</h4>
            <p><strong>Schedule I</strong> - Narcotic controlled substance. Prescription required with strict regulations. Part of national opioid strategy monitoring.</p>
          </div>
          <div class="jurisdiction">
            <h4>氈E氈E Australia</h4>
            <p><strong>Schedule 8</strong> - Controlled drug, restricted availability. Requires special authority in most states. Real-time prescription monitoring.</p>
          </div>
        </div>
        
        <div class="regulatory-response">
          <h4>沛･ Regulatory Response to Abuse</h4>
          <p><strong>FDA actions:</strong> Opana ER reformulated with abuse-deterrent technology after injection epidemic. <strong>Market withdrawal:</strong> Original Opana ER withdrawn from market in 2017 due to public health risks. <strong>Prescribing restrictions:</strong> Enhanced monitoring and limited prescribing for legitimate medical use. <strong>Public health measures:</strong> Needle exchange programs and HIV testing in affected communities.</p>
          
          <h4>沒 Legal Penalties</h4>
          <p><strong>Healthcare diversion:</strong> Loss of medical license, felony charges, prison sentences. <strong>Prescription fraud:</strong> Doctor shopping, forged prescriptions carry federal penalties. <strong>Distribution:</strong> Trafficking charges with mandatory minimum sentences for quantities. <strong>Public health crimes:</strong> Disease transmission through drug sharing prosecuted as assault.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>沒 History & Medical Development</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1914</span>
          <p>First synthesized in Germany as morphine derivative</p>
        </div>
        <div class="history-event">
          <span class="year">1950s</span>
          <p>FDA approval for severe pain management</p>
        </div>
        <div class="history-event">
          <span class="year">2006</span>
          <p>Extended-release Opana ER approved for chronic pain</p>
        </div>
        <div class="history-event">
          <span class="year">2010-2015</span>
          <p>Injection epidemic peaks in rural Appalachian communities</p>
        </div>
        <div class="history-event">
          <span class="year">2015</span>
          <p>Indiana HIV outbreak: 200+ cases traced to shared Opana injection</p>
        </div>
        <div class="history-event">
          <span class="year">2017</span>
          <p>FDA requests Opana ER removal from market due to public health risks</p>
        </div>
        <div class="history-event">
          <span class="year">2017-present</span>
          <p>Heavily restricted prescribing, abuse-deterrent formulations only</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Injection Epidemic Tragedy</h4>
        <p>Oxymorphone became synonymous with the devastating injection epidemic that destroyed rural Appalachian communities. The 2015 Indiana HIV outbreak, where over 200 people contracted HIV through shared Opana injection, marked a turning point in opioid policy and highlighted the catastrophic public health consequences of prescription opioid injection.</p>
        
        <h4>Pharmaceutical Response Failure</h4>
        <p>Despite attempts at abuse-deterrent formulations, oxymorphone continued to fuel injection epidemics. The failure of technological solutions to prevent abuse led to the unprecedented FDA request for market withdrawal of an approved opioid medication, demonstrating that some drugs may be too dangerous for any legitimate medical use.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>沐ｬ Current Research & Medical Applications</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Severe Pain Management</h4>
          <p>Limited research continues into oxymorphone's role in severe cancer pain and end-of-life care, where its extreme potency may be medically justified despite abuse risks. Focus on identifying patients who truly need this level of analgesia.</p>
        </div>
        
        <div class="research-item">
          <h4>Abuse-Deterrent Technology</h4>
          <p>Development of more sophisticated tamper-resistant formulations that prevent crushing, dissolving, and injection. However, the 2017 market withdrawal suggests technological solutions may be insufficient for this compound.</p>
        </div>
        
        <div class="research-item">
          <h4>Injection Epidemic Studies</h4>
          <p>Ongoing epidemiological research into the long-term health consequences of the oxymorphone injection epidemic, including HIV/Hepatitis treatment outcomes and community recovery strategies.</p>
        </div>
        
        <div class="research-item">
          <h4>Alternative Analgesics</h4>
          <p>Research into safer alternatives for the severe pain conditions that might otherwise require oxymorphone, including novel non-opioid analgesics and multimodal pain management approaches.</p>
        </div>
      </div>

      <div class="medical-applications">
        <h4>沛･ Limited Medical Uses</h4>
        <div class="medical-uses">
          <div class="medical-use">
            <h5>Restricted Pain Management</h5>
            <ul>
              <li><strong>End-stage cancer pain:</strong> When other opioids inadequate for terminal patients</li>
              <li><strong>Severe breakthrough pain:</strong> Short-term use in opioid-tolerant patients</li>
              <li><strong>Palliative care:</strong> Comfort care when quality of life outweighs addiction risk</li>
              <li><strong>Post-surgical pain:</strong> Very limited use in complex surgical procedures</li>
            </ul>
          </div>
          
          <div class="medical-use">
            <h5>Specialized Protocols</h5>
            <ul>
              <li><strong>Hospital-only administration:</strong> Restricted to inpatient settings with monitoring</li>
              <li><strong>Addiction medicine consultation:</strong> Required assessment before prescribing</li>
              <li><strong>Enhanced monitoring:</strong> Frequent follow-up and drug testing</li>
              <li><strong>Limited quantity prescribing:</strong> Short-term supply with no refills</li>
            </ul>
          </div>
          
          <div class="medical-use">
            <h5>Public Health Considerations</h5>
            <ul>
              <li><strong>Community risk assessment:</strong> Prescribing restricted in high-risk areas</li>
              <li><strong>Needle exchange access:</strong> Communities with oxymorphone use need harm reduction</li>
              <li><strong>Blood-borne disease screening:</strong> Enhanced testing in affected populations</li>
              <li><strong>Alternative treatment priority:</strong> Exhaust all other options before consideration</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>沒 Medical & Crisis Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Emergency & Crisis</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/find-help/national-helpline">SAMHSA National Helpline</a> - 24/7 treatment referral and crisis support</li>
          <li><a href="https://www.naloxoneforall.org/">Naloxone for All</a> - Overdose reversal training and distribution</li>
          <li><a href="https://www.cdc.gov/hiv/risk/drugs/">CDC Drug Use & HIV Risk</a> - Prevention and testing resources</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Treatment Resources</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/medication-assisted-treatment">MAT Provider Locator</a> - Find medication-assisted treatment</li>
          <li><a href="https://www.na.org/">Narcotics Anonymous</a> - Peer support recovery meetings</li>
          <li><a href="https://www.hep-druginteractions.org/">Hepatitis Drug Interactions</a> - Treatment planning for co-occurring conditions</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction</h4>
        <ul>
          <li><a href="https://harmreduction.org/">Harm Reduction Coalition</a> - Needle exchange and safer use resources</li>
          <li><a href="https://www.cdc.gov/hiv/testing/">HIV Testing Locator</a> - Find confidential testing sites</li>
          <li><a href="https://www.hepatitis.va.gov/">Hepatitis C Resources</a> - Treatment and prevention information</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="medical-context">
    <h3>沛･ Medical Context & Public Health Impact</h3>
    <div class="medical-info-grid">
      <div class="medical-info-item">
        <h4>Pharmaceutical Tragedy</h4>
        <p>Oxymorphone represents one of the most tragic examples of prescription opioid abuse consequences. Despite legitimate medical applications for severe pain, its extreme euphoric potential and injection abuse led to devastating public health crises that destroyed entire rural communities.</p>
      </div>
      
      <div class="medical-info-item">
        <h4>Regulatory Lessons</h4>
        <p>The 2017 FDA request for Opana ER market withdrawal marked the first time regulators determined that an approved opioid's risks outweighed all benefits. This precedent demonstrates that some medications may be too dangerous for any commercial availability.</p>
      </div>
      
      <div class="medical-info-item">
        <h4>Community Recovery</h4>
        <p>Communities affected by the oxymorphone injection epidemic continue recovery efforts including expanded addiction treatment, needle exchange programs, HIV/Hepatitis care, and economic revitalization. Recovery requires comprehensive public health intervention and long-term community support.</p>
      </div>
    </div>
  </div>

</div>

